Telomir Pharmaceuticals, Inc. Common Stock (TELO) Stock Score, Valuation & Financial Research

Telomir Pharmaceuticals, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TELO

Telomir Pharmaceuticals, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 1.18. These figures are a research snapshot, not a buy or sell recommendation.

What Telomir Pharmaceuticals, Inc. Common Stock does

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of novel small molecule therapeutics, specifically its lead candidate Telomir-1, which is being investigated for potential applications in treating various conditions including metal-overload and other age-related diseases.

Products and services

  • The company's primary product candidate is Telomir-1, a small molecule therapeutic currently in preclinical development stages for potential use in treating conditions such as Wilson's disease and other metal-overload disorders.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct preclinical studies and clinical trials. Source

Business strengths to evaluate

  • Proprietary research on Telomir-1 molecular mechanisms Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Dependence on the success of a single lead product candidate Source
  • Requirement for significant additional capital to fund operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TELO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.18
Market capitalization:
81.15M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -5.88M
Free cash flow:
USD -3.69M
Cash:
USD 5.17M
Total debt:
USD 473.75K
EPS:
USD -1.51

What stands out

  • Free cash flow is USD -3.69M, negative for the stored period.
  • The balance sheet shows USD 5.17M of cash versus USD 473.75K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.7M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TELO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TELO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TELO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TELO to reach sustainable profitability?
  • What does the current share basis reconciled warning mean for the reliability or interpretation of TELO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TELO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.